SCM Life Science, Malaysian pharmaceutical company CCM Duofarma said, "Attracting 5.5 billion won in investment."
SCM Life Science Co., Ltd. (hereinafter referred to as SCM Life Science, CEO Lee Byung-gun) signed a joint research agreement on tissue regeneration treatments that directly transplants single cell-derived clone stem cell sheets into tissues using “Subfractionation Culturing Method” (CSTEC) in Utah University's healthcare system local time on the 10th.
SCM Life Science is a stem cell therapy
company with original technology in the field of high-purity isolation and
culture of adult stem cells. And The Cell Sheet Tissue Engineering Center
(CSTEC), an integrated research team at Utah University Medical School and
Pharmacy that developed heart disease treatments based on cell sheet tissue
engineering, has signed a joint research agreement to develop and function in
the U.S.
"Our research team is focusing on the
development of stem cell sheet tissue engineering technology for regenerative
treatment," said Teruo Okano, head of the CSTEC center. "We want to
develop innovative treatments for many patients around the world who need
regenerative treatment through the convergence of high-purity mesenchymal stem
cell and cell sheet tissue engineering technology using SCM Life Science."
We plan to provide technology and funding
for CSTEC's joint research on cell sheet tissue engineering, said Lee
Byung-gun, CEO of SCM Life Science. "We hope to develop new technologies
that combine mutual technologies to lead new regenerative medicine through
successful clinical and commercialization."
Meanwhile, SCM Life Science is focusing on
the development of next-generation stem cell treatments for autoimmune
diseases, an intractable disease, and has continued research for more than 10
years based on its own source technology for adult mesenchyma stem cell
separation and culture. Through this, patents have been registered in major
countries, including the United States, the EU, Japan, and China, and are
currently focusing on developing cell therapies such as chronic and acute Graft
versus host disease (GVHD), severe acute pancreatitis, severe atopic
dermatitis, and severe cirrhosis.